Article

Mechanisms of resistance to active state selective tri-complex RAS inhibitors

2025-04-26

Abstract excerpt

Tri-complex inhibitors (TCIs) act as molecular glues to recruit cyclophilin A (CYPA) to the active (GTP-bound or ON) conformation of RAS, which in turn prevents the activation of downstream effector proteins like RAF and PI3K. Emerging data demonstrate clinical activity, including tumor regressions, in patients with RAS driven cancers. Despite being promising therapeutic interventions, the mechanisms of resistance...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e4751887-9194-5b69-b299-2070cc39950d
DOI: 10.1101/2025.04.24.649345

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of resistance to active state selective tri-complex RAS inhibitorsDOI 10.1101/2025.04.24.649345Read

Disrupted molecular glue complex drives RAS inhibitor resistance.Semantic proximity Read

Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance.Semantic proximity Read

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.Semantic proximity Read

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.Semantic proximity Read

Anticancer drug resistance: An update and perspective.Semantic proximity Read

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapySemantic proximity Read

RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade.Semantic proximity Read

RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer.Semantic proximity Read

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.Semantic proximity Read

SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.Semantic proximity Read

Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.Semantic proximity Read

Mechanisms of targeted therapy resistance take a de-TOR.Semantic proximity Read